Cooperative Agreement U48DP006876

Award Date 9/30/24
Completion Date 9/29/26
Dollars Obligated $250K
Awarding Federal Agency
Office of Financial Resources
Federal Grant Program
93.135
Assistance Type
Cooperative Agreement
Place of Performance
Minneapolis, MN, USA
Similar Awards
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $349,950 Cooperative Agreement under the Centers for Research and Demonstration for Health Promotion and Disease Prevention (CFDA 93.135) program to the Regents of the University of Minnesota. The award, effective September 30, 2024 through September 29, 2026, supports research to understand the impact of survivorship care plans on health outcomes in cancer survivors. As a prominent land-grant research institution, the...
The University of Minnesota has been awarded a $2,998,086 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the Assistance Programs for Chronic Disease Prevention and Control (CFDA 93.945) federal grant program. The five-year award, effective September 30, 2024, will support the University of Minnesota Prevention Research Center in conducting research, interventions, and public health initiatives targeting chronic diseases. The program aims to enhance...
This $1,193,768 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under CFDA 93.135 "Centers for Research and Demonstration for Health Promotion and Disease Prevention" supports the Massachusetts Cancer Prevention and Control Research Network. The award will fund applied public health research at the Harvard T.H. Chan School of Public Health, including activities such as: Designing community-engaged cancer prevention and control strategies to improve...
This federal Cooperative Agreement award, identified as U48DP006848, was granted by the Centers for Disease Control and Prevention (CDC) under the Centers for Research and Demonstration for Health Promotion and Disease Prevention (CFDA 93.135) program. The $299,996.00 award was granted to New York University (NYU) on September 30, 2024, with a performance period running through September 29, 2029. Under this Cooperative Agreement, NYU will conduct applied public health research to develop, test,...
This federal Cooperative Agreement award of $2,000,000.00 was granted by the National Center for Chronic Disease Prevention and Health Promotion, part of the Centers for Disease Control and Prevention (CDC), under the Assistance Programs for Chronic Disease Prevention and Control (CFDA 93.945) program. The award, with a start date of September 30, 2024 and an ultimate completion date of September 29, 2029, will support the Prevention Research Center at the University of Massachusetts Medical...
The National Cancer Institute (NCI) awarded a $386,700 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the Regents of the University of Minnesota. The grant, titled "Preclinical Development and Validation of Targeted Mass Spectrometry Assays for Serous Ovarian Cancer Diagnosis", will fund research to develop and validate novel multiplexed protein biomarker assays that can differentiate serous ovarian cancer patients from healthy individuals. The...
The Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) awarded a $459,993 Cooperative Agreement under the "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients" program (CFDA 93.376) to the University of Illinois. This 5-year award, effective September 30, 2024, will support the University of Illinois in developing and delivering comprehensive psychosocial and structural support services for young...
The federal Cooperative Agreement award, funded by the Centers for Disease Control and Prevention (CDC) under CFDA 93.376 "Multiple Approaches to Support Young Breast Cancer Survivors and Metastatic Breast Cancer Patients", provides $460,000.00 in funding to Weill Medical College of Cornell University over a 5-year period from September 30, 2024 to September 29, 2029. The award supports the development and implementation of comprehensive psychosocial and structural support services for...
This Cooperative Agreement award from the National Center for Chronic Disease Prevention and Health Promotion, part of the Centers for Disease Control and Prevention (CDC), provides $599,872.00 in funding to the University of Pennsylvania Prevention Research Center over a 5-year period from September 30, 2024 to September 29, 2029. The award supports the Prevention Research Centers' Cancer Prevention and Control Research Network, which conducts applied public health research to develop, test,...
The University of Iowa was awarded a $900,000 Cooperative Agreement under the Centers for Research and Demonstration for Health Promotion and Disease Prevention (CFDA 93.135) program by the Centers for Disease Control and Prevention (CDC). The award, effective September 30, 2024 through September 29, 2029, supports the UI Cancer Prevention and Control Research Network Collaborating Center. The purpose of this academic research center is to conduct applied public health research to develop, test,...

This Cooperative Agreement award of $250,000, effective September 30, 2024 through September 29, 2026, was granted by the Centers for Disease Control and Prevention (CDC) under the federal Centers for Research and Demonstration for Health Promotion and Disease Prevention (CFDA 93.135) program. The award supports a research project titled "UNTOLD: UNDERSTANDING THE EXPERIENCE OF OVARIAN CANCER – LIFE AFTER DIAGNOSIS: A MIXED METHODS APPROACH" to be conducted by the Regents of the University of Minnesota. The project aims to develop, test, evaluate, and translate interventions that address major causes of illness, disability, and death in the United States, with a focus on improving population health outcomes and reducing health disparities related to ovarian cancer. As a Prevention Research Center, the University of Minnesota will leverage its academic and research capabilities to carry out this mixed methods study examining the experience of ovarian cancer patients following diagnosis.

Generated 8/5/25, 4:53 AM